eMedicine Specialties > Urology > Cancer, Testicle

Nonseminomatous Testicular Tumors

Author: David M Hoenig, MD, Associate Professor, Department of Urology, Albert Einstein College of Medicine; Chief of Weiler Division, Director of Laparoscopy and Endourology, Co-Director of Fellowship in Laparoscopy and Endourology, Residency Program Director, Department of Urology, Montefiore Medical Center
Coauthor(s): Janice Angela Santos-Cortes, MD, Chief Resident, Department of Urology, Albert Einstein Program, Montefiore Medical Center; Thomas H Rechtschaffen, MD, Consulting Staff, Department of Urology, A Family Urology Practice, PC
Contributor Information and Disclosures

Updated: Nov 11, 2008

Introduction

Testicular cancer is relatively uncommon in the United States, with approximately 5500 cases per year. The overall incidence of testicular tumors worldwide ranges from 0.2-10.3 cases per 100,000 persons. Such tumors may arise in males of nearly any age and may be of germ cell or non–germ cell origin. Tumor histology (see Histologic Findings) and tumor stage (see Staging) are of primary importance in determining the prognosis of testicular tumors. This article addresses the demographics, histology, prognosis, and treatment of nonseminomatous germ cell tumors (NSGCTs).

History of the Procedure

The treatment of testicular cancer has developed in earnest over the past half century. Before 1970, testicular tumors carried a mortality rate that approached 50%, whereas recent studies have reported that the cure rate using multimodal therapy exceeds 90%. Improved understanding of the histology, mechanisms of tumor spread, and tumor markers, combined with the improved quality of radiographic imaging for accurate staging, have greatly contributed to the management of testicular cancer. The combination of refinements in surgical intervention and the application of effective combination chemotherapy has emerged as a paradigm for the successful use of multimodal therapy for solid tumors.

Problem

Testicular cancer has 3 main types—(1) germ cell tumors, (2) non–germ cell tumors, and (3) extragonadal tumors. Germ cell tumors, which are the most common, are classified as either seminoma or nonseminoma, based on histology. Of the 3 main types of testicular cancer, NSGCTs are behind only seminoma in terms of frequency. This discussion explores the incidence, risk factors, diagnosis, treatment options, and prognosis of NSGCTs.

Frequency

US incidence

Testicular cancer is relatively uncommon, with approximately 5500 new cases per year in the United States. The peak incidence is in men aged 20-34 years. Testicular cancer is the most common solid tumor in this otherwise young, healthy, and productive age group. Furthermore, despite improvements in survival rates since the introduction of platinum-based chemotherapy in the United States in the 1970s and 1980s, from 1975-2001, the incidence of testicular cancer among white males in the United States rose by 46%. Currently, the incidence is approximately 5.44 cases per 100,000 persons.1

The rate of NSGCTs specifically also appears to have increased. In addition, the incidence of NSGCTs among active servicemen in the military almost doubled from 1988-1996.2 NSGCTs are less common in African American males than in white males.

International incidence

Worldwide, testicular cancer has the highest incidence in Norway, Denmark, Germany, and Switzerland. The incidence in Switzerland in 1997 was 10.3 cases per 100,000 persons, with NSGCTs accounting for 45%-50% of cases. The incidence in this population has increased alarmingly (>300%) since 1955. The risk for the disease has increased in all birth cohorts except for those born during World War II.

Etiology

Factors that alter the differentiation of the primordial germ cell, resulting in the presence of an embryonal stem cell, can increase the risk of NSGCT. Risk factors include a history of testicular cancer in the contralateral testis, cryptorchidism (undescended testis), gonadal dysgenesis, prenatal exposure to high estradiol levels, exposure to chemical carcinogens, trauma, and orchitis. Other risk factors may include childhood inguinal hernias and any cause of testicular atrophy.

In 2005, a 25-year follow-up study of 44,864 Swedish men suggested that elevated serum cholesterol levels may increase the risk of testicular cancer.3 Further validation studies are required to evaluate these findings in other populations.

One of the most significant risk factors for testicular cancer is cryptorchidism. In addition, the age at which orchidopexy (an operation to bring the testicle down into the scrotum) is performed appears to play a significant role. A 2007 study reported a 2.23 relative risk (in comparison with the general Swedish population) of testicular cancer in patients who underwent orchidopexy before age 13 years, while the relative risk among those who underwent orchidopexy at age 13 years or older was 5.40.4 Therefore, among boys with cryptorchidism, orchidopexy performed before puberty appears to reduce the likelihood of testicular cancer later in life.

Pathophysiology

NSGCTs refer to the germ cell tumors that contain embryonal stem cells. These may be differentiated into extraembryonic tissues or somatic elements. Most tumors are composed of a mixture of these elements.

The 4 histologic classifications of NSGCTs include (1) embryonal carcinoma, (2) teratoma, (3) choriocarcinoma, and (4) yolk sac tumor.

Mixed tumors are those with a mixture of these histologies. Tumors with both seminomatous and nonseminomatous elements are considered NSGCTs because the NSGCT component most accurately reflects the response to treatment and overall prognosis.

Presentation

The classic presentation of a testicular tumor is a painless, swollen, hard testis in an otherwise healthy man in the third or fourth decade of life. The presentation can vary depending on the amount of disease, clinical stage, and the presence of metastases at the time of referral. Some patients present with a swollen painful mass in the scrotum that may be dismissed as infectious or inflammatory in nature, potentially resulting in a detrimental delay in starting treatment for NSGCT. Whenever the physical examination reveals any deviation from a palpably normal testicle, scrotal ultrasonography should be performed.

In all patients in whom testicular tumors are suspected, obtain a complete history and perform a complete physical examination. The history should include specific questions regarding possible risk factors for testicular cancer. Questions about cryptorchidism, trauma, and mumps orchitis are useful. Likewise, the occupational, chemical exposure, and smoking history of the patient should be obtained.

During the general physical examination, special attention should be given to the presence of gynecomastia, which is a finding in 5% of testicular cancer cases. Supraclavicular adenopathy may be a finding in advanced disease. Lung examination in patients with widespread lung metastases may reveal areas of decreased breath sounds. Abdominal examination should be performed to assess for visceral or bulky lymphatic involvement. The contralateral testis must be examined for possible abnormalities. Finally, a neurologic examination is also important to evaluate for possible brain metastasis. The testicles should be readily palpable in the scrotum. The contour of each testicle should be smooth and the consistency uniform. Any size discrepancy between the 2 testicles should be assessed and noted.

Differentiation of the scrotal contents should be found with careful palpation. The epididymis, attached to the posterior aspect of the testicle, is frequently the site of induration or cysts. Patients may discover such abnormalities during self-examination, prompting them to seek medical attention. These conditions should be identifiable during the physical examination. If the inability to perform an adequate evaluation is a concern, scrotal ultrasonography must be performed to aid in the diagnosis.

Indications

Surgery is indicated not only for the initial treatment of nonseminomatous germ cell tumors (NSGCTs) but also for diagnosis.

Relevant Anatomy

See Clinical.

Contraindications

Radical (inguinal) orchiectomy has no contraindications, other than potential anesthetic risks and uncontrolled bleeding diathesis. In such high-risk patients, preoperative clearance and preparation may be required, but radical orchiectomy should still be performed at the earliest opportunity.

More on Nonseminomatous Testicular Tumors

Overview: Nonseminomatous Testicular Tumors
Workup: Nonseminomatous Testicular Tumors
Treatment: Nonseminomatous Testicular Tumors
Follow-up: Nonseminomatous Testicular Tumors
References
[ CLOSE WINDOW ]

References

  1. Sokoloff MH, Joyce GF, Wise M. Testis cancer. J Urol. Jun 2007;177(6):2030-41. [Medline].

  2. Thompson IM, Optenberg S, Byers R, et al. Increased incidence of testicular cancer in active duty members of the Department of Defense. Urology. Apr 1999;53(4):806-7. [Medline].

  3. Wirehn AB, Tornberg S, Carstensen J. Serum cholesterol and testicular cancer incidence in 45,000 men followed for 25 years. Br J Cancer. May 9 2005;92(9):1785-6. [Medline].

  4. Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. May 3 2007;356(18):1835-41. [Medline].

  5. Beck SD, Foster RS, Bihrle R, Donohue JP. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors. Urology. Mar 2007;69(3):557-9. [Medline].

  6. Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. Apr 10 2007;25(11):1310-5. [Medline].

  7. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. Apr 20 2005;23(12):2781-8. [Medline].

  8. Horwich A, Norman A, Fisher C, et al. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol. Jan 1994;151(1):72-7; discussion 77-8. [Medline].

  9. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. Feb 10 2007;25(5):513-6. [Medline].

  10. Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?. J Urol. 1998;160:1347-52. [Medline].

  11. Ehrlich Y, Baniel J. Late relapse of testis cancer. Urol Clin North Am. May 2007;34(2):253-8; abstract x-xi. [Medline].

  12. Stava C, Beck M, Schultz PN, et al. Hearing loss among cancer survivors. Oncol Rep. Jun 2005;13(6):1193-9. [Medline].

  13. Mykletun A, Dahl AA, Haaland CF, et al. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol. May 1 2005;23(13):3061-8. [Medline].

  14. Bahadur G, Ozturk O, Muneer A, Wafa R, Ashraf A, Jaman N, et al. Semen quality before and after gonadotoxic treatment. Hum Reprod. Mar 2005;20(3):774-81. [Medline].

  15. Phillips N, Jequier AM. Early testicular cancer: a problem in an infertility clinic. Reprod Biomed Online. Nov 2007;15(5):520-5. [Medline].

  16. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol. Nov 2005;174(5):1819-22; discussion 1822. [Medline].

  17. Spermon JR, Kiemeney LA, Meuleman EJ, et al. Fertility in men with testicular germ cell tumors. Fertil Steril. Jun 2003;79 Suppl 3:1543-9. [Medline].

  18. Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer. Feb 15 2004;100(4):732-7. [Medline].

  19. Agarwal A, Sidhu RK, Shekarriz M, et al. Optimum abstinence time for cryopreservation of semen in cancer patients. J Urol. Jul 1995;154(1):86-8. [Medline].

  20. Janetschek G, Hobisch A, Peschel R, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol. Jun 2000;163(6):1793-6. [Medline].

  21. Neyer M, Peschel R, Akkad T, et al. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol. Feb 2007;21(2):180-3. [Medline].

  22. Shayegan B, Carver BS, Stasi J, et al. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU Int. May 2007;99(5):993-7. [Medline].

  23. Permpongkosol S, Lima GC, Warlick CA, et al. Postchemotherapy laparoscopic retroperitoneal lymph node dissection: evaluation of complications. Urology. Feb 2007;69(2):361-5. [Medline].

  24. Agarwal A, Allamaneni SS. Disruption of spermatogenesis by the cancer disease process. J Natl Cancer Inst Monogr. 2005;9-12. [Medline].

  25. American Joint Committee on Cancer. Manual for Staging Cancer. 5th ed. Chicago, Ill: American Joint Committee on Cancer; 1997.

  26. Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. December/1995;31A (13-14):2229-38. [Medline].

  27. Boyer M, Raghavan D. Toxicity of treatment of germ cell tumors. Semin Oncol. Apr 1992;19(2):128-42. [Medline].

  28. Choueiri TK, Stephenson AJ, Gilligan T, et al. Management of clinical stage I nonseminomatous germ cell testicular cancer. Urol Clin North Am. May 2007;34(2):137-48; abstract viii. [Medline].

  29. De Giorgi U, Pupi A, Fiorentini G, et al. FDG-PET in the management of germ cell tumor. Ann Oncol. May 2005;16 Suppl 4:iv90-94. [Medline].

  30. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. Mar 15 2001;19(6):1629-40. [Medline].

  31. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am. Aug 1998;25(3):461-8. [Medline].

  32. Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A non- seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol. Mar 1993;71(3):326-35. [Medline].

  33. Droz JP, Kramar A, Rey A. Prognostic factors in metastatic disease. Semin Oncol. Apr 1992;19(2):181-9. [Medline].

  34. Eggener SE, Carver BS, Sharp DS, et al. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. Mar 2007;177(3):937-42; discussion 942-3. [Medline].

  35. Feldman DR, Bosl GJ, Sheinfeld J, et al. Medical treatment of advanced testicular cancer. JAMA. Feb 13 2008;299(6):672-84. [Medline].

  36. Fossa SD, Ous S, Abyholm T, et al. Post-treatment fertility in patients with testicular cancer. II. Influence of cis-platin-based combination chemotherapy and of retroperitoneal surgery on hormone and sperm cell production. Br J Urol. Apr 1985;57(2):210-4. [Medline].

  37. Foster RS, Donohue JP. Surgical treatment of clinical stage A nonseminomatous testis cancer. Semin Oncol. Apr 1992;19(2):166-70. [Medline].

  38. Frohlich MW, Small EJ. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am. Aug 1998;25(3):451-9. [Medline].

  39. Gandini L, Sgro P, Lombardo F, et al. Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients. Hum Reprod. Nov 2006;21(11):2882-9. [Medline].

  40. Garner MJ, Turner MC, Ghadirian P, et al. Epidemiology of testicular cancer: an overview. Int J Cancer. Sep 1 2005;116(3):331-9. [Medline].

  41. Gerl A, Clemm C, Lamerz R, et al. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease. Eur J Cancer. 1993;29A(7):961-5. [Medline].

  42. Grossfeld GD, Small EJ. Long-term side effects of treatment for testis cancer. Urol Clin North Am. Aug 1998;25(3):503-15. [Medline].

  43. Hay JH, Duncan W, Kerr GR. Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol. Jul 1984;57(679):597-602. [Medline].

  44. Hogeboom WR, Hoekstra HJ, Mooyaart EL, et al. The role of magnetic resonance imaging and computed tomography in the treatment evaluation of retroperitoneal lymph-node metastases of non-seminomatous testicular tumors. Eur J Radiol. Jul-Aug 1991;13(1):31-6. [Medline].

  45. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. May 1997;15(5):1844-52. [Medline].

  46. Jewett M, Lange P, Raghavan D. Controversies in the Treatment of Early Stage Nonseminomatous Testicular Cancer. In: Raghavan D, Scher H, Leibel S, Lange P, eds. Principles and Practice of Genitourinary Oncology. Philadelphia, Pa: Lippincott-Raven; 1997:706.

  47. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. Feb 1998;16(2):692-701. [Medline].

  48. Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide [published erratum appears in Ann Intern Med 1988 Nov 15;109(10):846]. Ann Intern Med. Oct 1 1988;109(7):540-6. [Medline].

  49. Marth D, Scheidegger J, Studer UE. Ultrasonography of testicular tumors. Urol Int. 1990;45(4):237-40. [Medline].

  50. McKiernan JM, Goluboff ET, Liberson GL, et al. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol. Aug 1999;162(2):361-3. [Medline].

  51. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. Jan 20 2007;25(3):247-56. [Medline].

  52. O'Sullivan JM, Huddart RA, Norman AR, et al. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. Jan 2003;14(1):91-6. [Medline].

  53. Oh JH, Baum DD, Pham S, Cox M, Nguyen ST, Ensor J, et al. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Onc. 2007;24(2):175-81. [Medline].

  54. Pizzocaro G, Zanoni F, Milani A, et al. Orchiectomy alone in clinical stage I nonseminomatous testis cancer: a critical appraisal. J Clin Oncol. Jan 1986;4(1):35-40. [Medline].

  55. Ray B, Hajdu SI, Whitmore WF Jr. Proceedings: Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer. Feb 1974;33(2):340-8. [Medline].

  56. Robinson D, Moller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer. Feb 12 2007;96(3):529-33. [Medline].

  57. Sakamoto H, Oohta M, Inoue K, et al. Testicular sperm extraction in patients with persistent azoospermia after chemotherapy for testicular germ cell tumor. Int J Urol. Feb 2007;14(2):167-70. [Medline].

  58. Sanchez D, Zudaire JJ, Fernandez JM, et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int. Jun 2002;89(9):912-6. [Medline].

  59. Sandeman TF. Symptoms and early management of germinal tumours of the testis. Med J Aust. Sep 22 1979;2(6):281-4. [Medline].

  60. Schmidt KL, Carlsen E, Andersen AN. Fertility treatment in male cancer survivors. Int J Androl. Aug 2007;30(4):413-8; discussion 418-9. [Medline].

  61. Sibert L, Rives N, Rey D, et al. Semen cryopreservation after orchidectomy in men with testicular cancer. BJU Int. Dec 1999;84(9):1038-42. [Medline].

  62. Stephenson RA. Surveillance for clinical stage I nonseminomatous testis carcinoma: rationale and results. Urol Int. 1991;46(3):290-3. [Medline].

  63. Sturgeon JF, Jewett MA, Alison RE, et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol. Apr 1992;10(4):564-8. [Medline].

  64. Swerdlow AJ. Epidemiology of Testicular Cancer. In: Raghavan D, Scher H, Leibel S, Lange P, eds. Principles and Practice of Genitourinary Oncology. Philadelphia, Pa: Lippincott-Raven; 1997:643-52.

  65. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol. Oct 1988;6(10):1597-603. [Medline].

  66. Toklu C, Ozen H, Sahin A, et al. Factors involved in diagnostic delay of testicular cancer. Int Urol Nephrol. 1999;31(3):383-8. [Medline].

  67. Trigo JM, Tabernero JM, Paz-Ares L, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer. Jan 1 2000;88(1):162-8. [Medline].

  68. Tsili AC, Tsampoulas C, Giannakopoulos X, et al. MRI in the histologic characterization of testicular neoplasms. AJR Am J Roentgenol. Dec 2007;189(6):W331-7. [Medline].

  69. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. Oct 1 2007;25(28):4370-8. [Medline].

  70. Venkitaraman R, Johnson B, Huddart RA, et al. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int. Jul 2007;100(1):30-2. [Medline].

  71. Wanderas EH, Tretli S, Fossa SD. Trends in incidence of testicular cancer in Norway 1955-1992. Eur J Cancer. Nov 1995;31A(12):2044-8. [Medline].

  72. Winfield HN. Laparoscopic retroperitoneal lymphadenectomy for cancer of the testis. Urol Clin North Am. Aug 1998;25(3):469-78. [Medline].

  73. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. Jan-Feb 1995;45(1):8-30. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

testicular tumor, nonseminomatous testicular tumor, testis cancer, testicular cancer, testis mass, testicular mass, nonseminomatous germ cell tumor, non-seminomatous germ cell tumor, non-seminoma germ cell tumor, nonseminoma germ cell tumor, NSGCT, nonseminomatous germ cell testicular tumor, nonseminomatous testicular germ cell tumor, NSGCTT, NSTGCT, seminoma, nonseminoma, embryonal carcinoma, teratoma, choriocarcinoma, yolk sac tumor, cryptorchidism, testicular trauma, mumps orchitis, gynecomastia, orchiectomy

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

David M Hoenig, MD, Associate Professor, Department of Urology, Albert Einstein College of Medicine; Chief of Weiler Division, Director of Laparoscopy and Endourology, Co-Director of Fellowship in Laparoscopy and Endourology, Residency Program Director, Department of Urology, Montefiore Medical Center
David M Hoenig, MD is a member of the following medical societies: American Urological Association and Endourological Society
Disclosure: Boston Scientific Grant/research funds Consulting; Endocare Consulting fee Speaking and teaching; Applied Medical Consulting fee Speaking and teaching

Coauthor(s)

Janice Angela Santos-Cortes, MD, Chief Resident, Department of Urology, Albert Einstein Program, Montefiore Medical Center
Janice Angela Santos-Cortes, MD is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Nothing to disclose.

Thomas H Rechtschaffen, MD, Consulting Staff, Department of Urology, A Family Urology Practice, PC
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Omeros Corporation Consulting fee Consulting

Chief Editor

Bradley Fields Schwartz, DO, FACS, Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine
Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.